<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Oragenics Inc. — News on 6ix</title>
<link>https://6ix.com/company/oragenics-inc</link>
<description>Latest news and press releases for Oragenics Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 20 Apr 2026 13:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/oragenics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d7740551cc36e47533ea8b.webp</url>
<title>Oragenics Inc.</title>
<link>https://6ix.com/company/oragenics-inc</link>
</image>
<item>
<title>Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury</title>
<link>https://6ix.com/company/oragenics-inc/news/oragenics-reports-8-study-drug-doses-in-phase-iia-clinical-trial-of-onp-002-for-mild-traumatic-brain-injury</link>
<guid isPermaLink="true">https://6ix.com/company/oragenics-inc/news/oragenics-reports-8-study-drug-doses-in-phase-iia-clinical-trial-of-onp-002-for-mild-traumatic-brain-injury</guid>
<pubDate>Mon, 20 Apr 2026 13:00:00 GMT</pubDate>
<description>• Enrollment underway at Mackay Base Hospital in Queensland, Australia; additional sites in final activation stages SARASOTA, Fla., April 20, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today announced that 2 patients and 8 study drug doses have been administered in its ongoing Phase IIa clinical trial evaluating ONP-002, the Company’s lead candida</description>
</item>
<item>
<title>Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury</title>
<link>https://6ix.com/company/oragenics-inc/news/oragenics-doses-first-patient-in-phase-iia-clinical-trial-of-onp-002-for-mild-traumatic-brain-injury</link>
<guid isPermaLink="true">https://6ix.com/company/oragenics-inc/news/oragenics-doses-first-patient-in-phase-iia-clinical-trial-of-onp-002-for-mild-traumatic-brain-injury</guid>
<pubDate>Mon, 13 Apr 2026 12:30:00 GMT</pubDate>
<description>Mackay Base Hospital activated March 31, 2026 as first clinical trial site; first patient dosed within days of activation — a signal of strong enrollment velocity and significant unmet medical need SARASOTA, Fla., April 13, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today announced that the first patient has been dosed in its ongoing Phase IIa cli</description>
</item>
<item>
<title>Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation</title>
<link>https://6ix.com/company/oragenics-inc/news/oragenics-inc-receives-audit-opinion-with-going-concern-explanation</link>
<guid isPermaLink="true">https://6ix.com/company/oragenics-inc/news/oragenics-inc-receives-audit-opinion-with-going-concern-explanation</guid>
<pubDate>Wed, 25 Mar 2026 22:30:00 GMT</pubDate>
<description>SARASOTA, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal delivery technology, announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2025, which was filed on March 16, 2026 with the Securities and Exchange Commission, the audited consolidated financial statements contained an unqualified audit opinion from</description>
</item>
<item>
<title>ORAGENICS FILES ANNUAL REPORT ON FORM 10-K</title>
<link>https://6ix.com/company/oragenics-inc/news/oragenics-files-annual-report-on-form-10-k</link>
<guid isPermaLink="true">https://6ix.com/company/oragenics-inc/news/oragenics-files-annual-report-on-form-10-k</guid>
<pubDate>Tue, 17 Mar 2026 12:30:00 GMT</pubDate>
<description>REPORTS YEAR OF STRATEGIC TRANSFORMATION AND CLINCIAL ADVANCEMENT SARASOTA, Fla., March 17, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal delivery technology, today announced the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, with the U.S. Securities and Exchange Commission. In conjunction with this filing, the Company is providing</description>
</item>
<item>
<title>ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION</title>
<link>https://6ix.com/company/oragenics-inc/news/oragenics-initiates-phase-iia-clinical-trial-site-activation-10</link>
<guid isPermaLink="true">https://6ix.com/company/oragenics-inc/news/oragenics-initiates-phase-iia-clinical-trial-site-activation-10</guid>
<pubDate>Thu, 12 Mar 2026 12:30:00 GMT</pubDate>
<description>FIRST SITE INITIATION VISIT COMPLETED IN AUSTRALIA SARASOTA, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal delivery technology, today announced it has completed the first site initiation visit (SIV) for its Phase IIa clinical trial of ONP-002 in Australia. The visit marks the formal launch of clinical trial operations at the first of three planned trial s</description>
</item>
<item>
<title>ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION</title>
<link>https://6ix.com/company/oragenics-inc/news/oragenics-explores-expansion-of-cns-platform-pursuing-acquistion-of-assets-in-brain-health-recovery-and-neuroprotection-1</link>
<guid isPermaLink="true">https://6ix.com/company/oragenics-inc/news/oragenics-explores-expansion-of-cns-platform-pursuing-acquistion-of-assets-in-brain-health-recovery-and-neuroprotection-1</guid>
<pubDate>Wed, 11 Mar 2026 12:30:00 GMT</pubDate>
<description>SARASOTA, Fla., March 11, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal delivery technology, today announced that it is exploring discussions with third parties regarding the potential acquisition of additional assets in the central nervous system (CNS) space, with a specific focus on brain health and brain recovery indications that demonstrate strategic synergies with t</description>
</item>
<item>
<title>Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia</title>
<link>https://6ix.com/company/oragenics-inc/news/oragenics-receives-hrec-approval-for-phase-iia-clinical-trial-of-onp-002-as-a-treatment-for-concussion-and-mild-traumatic-brain-injury-in-australia-2</link>
<guid isPermaLink="true">https://6ix.com/company/oragenics-inc/news/oragenics-receives-hrec-approval-for-phase-iia-clinical-trial-of-onp-002-as-a-treatment-for-concussion-and-mild-traumatic-brain-injury-in-australia-2</guid>
<pubDate>Tue, 10 Mar 2026 12:30:00 GMT</pubDate>
<description>All required regulatory approvals secured for trial site onboarding and patient enrollment at three Australian sitesPotential first and only pharmacological treatment for the most prominent neurological condition without an FDA-approved therapeutic SARASOTA, Fla., March 10, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today announced that it has rec</description>
</item>
<item>
<title>Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy</title>
<link>https://6ix.com/company/oragenics-inc/news/oragenics-targets-projected-dollar9-billion-market-by-advancing-first-and-only-clinical-stage-concussion-and-mild-traumatic-brain-injury-therapy</link>
<guid isPermaLink="true">https://6ix.com/company/oragenics-inc/news/oragenics-targets-projected-dollar9-billion-market-by-advancing-first-and-only-clinical-stage-concussion-and-mild-traumatic-brain-injury-therapy</guid>
<pubDate>Mon, 09 Feb 2026 13:30:00 GMT</pubDate>
<description>Outlines clinical and growth catalysts for ONP-002 in concussion and mild traumatic brain injury (mTBI) Fully prepared to initiate near-term clinical site onboarding and first patient dosing in Australia Sarasota, Fla., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) (“the “Company”) a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today previewed its targeted milestones for 2026. Oragenics i</description>
</item>
<item>
<title>Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program</title>
<link>https://6ix.com/company/oragenics-inc/news/oragenics-partners-with-duck-flats-pharma-to-support-fda-ind-readiness-and-clinical-trial-design-for-concussion-program</link>
<guid isPermaLink="true">https://6ix.com/company/oragenics-inc/news/oragenics-partners-with-duck-flats-pharma-to-support-fda-ind-readiness-and-clinical-trial-design-for-concussion-program</guid>
<pubDate>Tue, 03 Feb 2026 13:30:00 GMT</pubDate>
<description>Collaboration reinforces regulatory diligence, nonclinical strategy and clinical trial integrity for novel intranasal concussion therapy Traumatic brain injuries affect more Americans each year than stroke, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and ALS combined Sarasota, Fla., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) (“the “Company”), a clinical-stage biotechnology company focused on developing intranasal therapeutics for neurological disord</description>
</item>
<item>
<title>Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care</title>
<link>https://6ix.com/company/oragenics-inc/news/oragenics-to-participate-in-scope-summit-2026-focused-on-advancing-clinical-research-and-patient-care</link>
<guid isPermaLink="true">https://6ix.com/company/oragenics-inc/news/oragenics-to-participate-in-scope-summit-2026-focused-on-advancing-clinical-research-and-patient-care</guid>
<pubDate>Mon, 02 Feb 2026 13:30:00 GMT</pubDate>
<description>Management to Engage with Global Clinical Research Leaders Ahead of Phase 2a Trial of Concussion Treatment Sarasota, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) (“the “Company”), a clinical-stage biotechnology company focused on developing intranasal therapeutics for neurological disorders, today announced its participation at the SCOPE Summit 2026, the 17th annual conference organized by the Cambridge Healthtech Institute. SCOPE (Summit for Clinical Ops Executi</description>
</item>
<item>
<title>Oragenics to Present at the 2026 Sequire Investor Summit in Puerto Rico</title>
<link>https://6ix.com/company/oragenics-inc/news/oragenics-to-present-at-the-2026-sequire-investor-summit-in-puerto-rico</link>
<guid isPermaLink="true">https://6ix.com/company/oragenics-inc/news/oragenics-to-present-at-the-2026-sequire-investor-summit-in-puerto-rico</guid>
<pubDate>Wed, 14 Jan 2026 13:30:00 GMT</pubDate>
<description>Sarasota, Fla., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) (“the “Company”) today announced that it will be presenting at the upcoming Sequire Investor Summit 2026. The fourth edition of the Sequire Investor Summit is scheduled for January 20th-22nd, 2026, at the Condado Vanderbilt Hotel in San Juan, Puerto Rico. “We appreciate the opportunity to present at the Sequire Investor Summit and discuss our novel approach to addressing the significant unmet medical need in</description>
</item>
<item>
<title>Oragenics Q3 2025 Shareholder Update</title>
<link>https://6ix.com/company/oragenics-inc/news/oragenics-q3-2025-shareholder-update</link>
<guid isPermaLink="true">https://6ix.com/company/oragenics-inc/news/oragenics-q3-2025-shareholder-update</guid>
<pubDate>Wed, 12 Nov 2025 13:30:00 GMT</pubDate>
<description>SARASOTA, Fla., November 12, 2025--Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today reported key operational, financial, and strategic achievements for the third quarter of 2025. These milestones reflect the Company's evolution from vision to execution as it advances toward critical clinical trial initiation in Q4 2025/Q1 2026.</description>
</item>
<item>
<title>Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency</title>
<link>https://6ix.com/company/oragenics-inc/news/oragenics-regains-full-nyse-american-compliance-company-resolves-stockholder-equity-deficiency</link>
<guid isPermaLink="true">https://6ix.com/company/oragenics-inc/news/oragenics-regains-full-nyse-american-compliance-company-resolves-stockholder-equity-deficiency</guid>
<pubDate>Tue, 21 Oct 2025 12:00:00 GMT</pubDate>
<description>SARASOTA, Fla., October 21, 2025--Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, announced today that it has regained full compliance with NYSE American’s continued listing standards and is positioning the Company to focus exclusively on advancing its lead clinical program.</description>
</item>
<item>
<title>Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development</title>
<link>https://6ix.com/company/oragenics-inc/news/oragenics-announces-strategic-partnership-with-receptorai-to-accelerate-pipeline-development</link>
<guid isPermaLink="true">https://6ix.com/company/oragenics-inc/news/oragenics-announces-strategic-partnership-with-receptorai-to-accelerate-pipeline-development</guid>
<pubDate>Tue, 07 Oct 2025 12:30:00 GMT</pubDate>
<description>SARASOTA, Fla., October 07, 2025--Oragenics, a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today announced a strategic collaboration with Receptor.AI, an artificial intelligence-driven drug profiling company, to accelerate the potential development of an expanded pharmaceutical-candidate portfolio for potential conditions affecting brain health.</description>
</item>
<item>
<title>Oragenics Q2 2025 Shareholder Update</title>
<link>https://6ix.com/company/oragenics-inc/news/oragenics-q2-2025-shareholder-update</link>
<guid isPermaLink="true">https://6ix.com/company/oragenics-inc/news/oragenics-q2-2025-shareholder-update</guid>
<pubDate>Mon, 11 Aug 2025 12:45:00 GMT</pubDate>
<description>Advancing Brain-First Recovery Platform Toward Clinical MilestonesPioneering Intranasal Therapeutics for Concussion SARASOTA, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a pioneering biotechnology company striving to develop brain-targeted therapeutics through proprietary intranasal delivery technology, today shared key strategic and financial milestones achieved during the second quarter of 2025 and shortly thereafter. These successes underscore the company's</description>
</item>
<item>
<title>Oragenics Selects Southern Star Research as Clinical Research Organization for ONP-002 Phase IIa Trial</title>
<link>https://6ix.com/company/oragenics-inc/news/oragenics-selects-southern-star-research-as-clinical-research-organization-for-onp-002-phase-iia-trial</link>
<guid isPermaLink="true">https://6ix.com/company/oragenics-inc/news/oragenics-selects-southern-star-research-as-clinical-research-organization-for-onp-002-phase-iia-trial</guid>
<pubDate>Thu, 31 Jul 2025 12:30:00 GMT</pubDate>
<description>Strategic CRO Partnership Supports Operational Readiness and Initiation of Upcoming Concussion StudySARASOTA, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering intranasal drug delivery for neurological conditions, today announced the selection of Southern Star Research as its Clinical Research Organization (CRO) for the upcoming Phase IIa clinical trial of ONP-002, the company’s lead drug candidate for concussion. Sou</description>
</item>
<item>
<title>Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development</title>
<link>https://6ix.com/company/oragenics-inc/news/oragenics-inc-announces-us-based-drug-manufacturing-agreement-to-support-onp-002-clinical-development</link>
<guid isPermaLink="true">https://6ix.com/company/oragenics-inc/news/oragenics-inc-announces-us-based-drug-manufacturing-agreement-to-support-onp-002-clinical-development</guid>
<pubDate>Wed, 16 Jul 2025 12:39:00 GMT</pubDate>
<description>SARASOTA, Fla., July 16, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today announced it has entered into a manufacturing agreement with Sterling Pharma Solutions, an industry leading CDMO with multiple US-based development and manufacturing facilities. Oragenics has partnered with Sterling Pharma Solutions for the GMP production of its lead drug candidate, ONP-002, for the treatment of co</description>
</item>
<item>
<title>Oragenics Completes Approximately $16.5 Million Offering</title>
<link>https://6ix.com/company/oragenics-inc/news/oragenics-completes-approximately-dollar165-million-offering</link>
<guid isPermaLink="true">https://6ix.com/company/oragenics-inc/news/oragenics-completes-approximately-dollar165-million-offering</guid>
<pubDate>Wed, 02 Jul 2025 20:15:00 GMT</pubDate>
<description>Proceeds to drive development of ONP-002, the Company’s lead intranasal drug candidate for mild traumatic brain injurySARASOTA, Fla., July 02, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering intranasal therapeutics for neurological disorders, today announced the successful closing of its previously announced public offering of Series H Convertible Preferred Stock and Warrants. The Company secured total gross proceeds of approximat</description>
</item>
<item>
<title>Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants</title>
<link>https://6ix.com/company/oragenics-inc/news/oragenics-inc-announces-pricing-of-public-offering-of-up-to-dollar20-million-of-preferred-stock-and-warrants</link>
<guid isPermaLink="true">https://6ix.com/company/oragenics-inc/news/oragenics-inc-announces-pricing-of-public-offering-of-up-to-dollar20-million-of-preferred-stock-and-warrants</guid>
<pubDate>Tue, 01 Jul 2025 12:31:00 GMT</pubDate>
<description>SARASOTA, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has entered into a placement agency agreement for the purchase and sale of up to 800,000 shares of the Company’s Series H Convertible Preferred Stock (“Preferred Stock”), no par value, and Warrants to purchase up to an additional 800,000 shares of Preferred Stock of the Comp</description>
</item>
<item>
<title>Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium</title>
<link>https://6ix.com/company/oragenics-inc/news/oragenics-to-present-at-2025-bio-international-convention-and-attend-42nd-annual-national-neurotrauma-society-symposium</link>
<guid isPermaLink="true">https://6ix.com/company/oragenics-inc/news/oragenics-to-present-at-2025-bio-international-convention-and-attend-42nd-annual-national-neurotrauma-society-symposium</guid>
<pubDate>Tue, 10 Jun 2025 12:30:00 GMT</pubDate>
<description>SARASOTA, Fla., June 10, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today announced that Greg Gironda, Head of Business Development, will present at the 2025 BIO International Convention, taking place June 16–19, 2025, in Boston, Massachusetts. In addition, Oragenics will also attend the 42nd Annual National Neurotrauma Society (NNS) Symposium, being held June 15–18, 2025, in Philadelphi</description>
</item>
</channel>
</rss>